External broker reports(aggregated public sources), Euroz Limited

Euroz Hartleys

A Western Australian diversified financial services company focused on providing financial services solutions to Institutional, Corporate & Private Clients. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Euroz Limited

Equity Bottom-Up

Botanix Pharmaceuticals / Equity Bottom-Up

<ul>
<li>The investment case remains unchanged.</li>
<li>The company has reaffirmed a mid-cycle review for the FDA New Drug Application (NDA) on Sofpironium Bromide remains on track for this quarter (Q1 CY23).</li>
<li>The mid-cycle review provides FDA management and review teams with an opportunity to identify any material issues relating to the NDA review which will be communicated to BOT and will serve to substantially de-risk the ultimate approval of Sofpironium Bromide, which remains on target for 3Q CY23.</li>
</ul>
<p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>


The investment case remains unchanged.
The company has reaffirmed a mid-cycle review for the FDA New Drug Application (NDA) on Sofpironium Bromide remains on track for this quarter (Q1 CY23).
The mid-cycle review provides FDA management and review teams with an opportunity to identify any material issues relating to the NDA review which will be communicated to BOT and will serve to substantially de-risk the ultimate approval of Sofpironium Bromide, which remains on target for 3Q CY23.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Botanix Pharmaceuticals Limited - Mid- Cycle Review Nears, FDA Approval On The Horizon